Amgen and ChemoCentryx, (maker of newly approved Avacopan)have entered into a definitive agreement wherein Amgen will acquire ChemoCentryx for ~$3.7 billion ($52 per share). https://t.co/8quO9ET8vH https://t.co/AphPizgKo8